Increased Scrutiny of U.S. Clinical Trials in China

SOURCE www.reuters.com
A bipartisan group of lawmakers called on the Biden administration to increase scrutiny of U.S. clinical trials conducted in China due to concerns about intellectual property theft and forced participation of Uyghurs. Reuters is the world's largest multimedia news provider.

Key Points

  • Bipartisan lawmakers urge Biden administration to ramp up scrutiny of U.S. clinical trials in China.
  • Concerns raised about intellectual property theft and forced participation of Uyghurs.
  • Reuters is the world's largest multimedia news provider.

Pros

  • Highlighting potential risks of intellectual property theft and forced Uyghur participation in clinical trials.